DOCSLIB.ORG

J&J Gains Full Control of OTC Joint Venture

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

OTC14-10-11p1.qxd 11/10/11 09:36 Page 1 14 October 2011 COMPANY NEWS 3 Japan’s Santen 3 J&J gains full control to buy Novagali EU approves P&G’s deal with Teva 3 Futura Medical on brink 4 of first product launches of OTC joint venture Actavis plots expansion 5 in Poland’s OTC market Celesio ends Medco joint venture 5 ohnson & Johnson has taken full control Ending the joint venture also provided great- Jof its consumer healthcare joint venture er freedom to operate in the OTC market, added Valeant’s new Afexa bid 6 tops Paladin Labs’ offer with Merck & Co in Canada and the US. Merck, allowing it to “fully exploit its pipeline Perrigo lays out global 7 The firm has paid US$175 million (C205 of prescription-to-OTC switches as well as ac- expansion plans million) for Merck’s 50% stake in the Johnson tively pursue OTC licensing activities in the McNeil considers next step 8 & Johnson/Merck Consumer Pharmaceuticals US and Canada”. after Motrin lawsuit defeat joint venture, which markets a range of OTC Set up in 1989 to develop, manufacture, mar- brands, primarily for digestive health. ket and distribute certain OTC products from GENERAL NEWS 9 Merck’s portfolio of prescription brands,the Pursue OTC licensing activities joint venture was Merck’s only presence in the Saw palmetto no better 9 Merck said that the deal allowed it to “fully OTC market prior to the Schering-Plough deal. than placebo focus on building the long-term growth pros- Meanwhile, Johnson & Johnson pointed out Turkey looks to abolish 10 pects” of its consumer healthcare business, that the deal gave its McNeil subsidiary exclu- its borderline category which was gained in 2009 when it acquired sive rights to the Mylanta, Mylicon and OTC Retail consolidation 10 Schering-Plough (OTC bulletin,16 Novem- Pepcid brands in the US, as well as 222, Fleet continues in Russia ber 2009, page 3). ■ Continued on page 15 Study links diclofenac 11 with heart attack Spain’s medicines agency 12 becomes autonomous body Beiersdorf recruits German committee MARKETING NEWS 13 Hero man as chief rejects pack curbs Aspirin drink heats up 13 German cold remedies eiersdorf has recruited Stefan Heidenre- proposal to restrict the maximum non-pre- It’s time to visit the 14 Bich – chief executive officer of the baby Ascription pack sizes of popular analgesics OTC Awards website food and jams manufacturer Hero Group – as to four days’ treatment has been rejected by the Pfizer extends Centrum with 15 its next chief executive officer. country’s Expert Committee for Prescription. Pregnancy Care line Heidenreich will take over from Thomas During an extraordinary meeting held on Quaas in April 2012. The German company 27 September,amajority of committee mem- FEATURES 17 noted that Quaas was stepping down as chief bers voted against introducing a restriction on Everyone’s talking about 17 executive officer after seven years in charge, the pack sizes for acetylsalicylic acid, diclo- switching – Switching was a but would remain a member of the supervi- fenac and ibuprofen, as well as for naproxen, hot topic as the leading global sory board. phenazone and propyphenazone (OTC bullet- OTC players reported their Beiersdorf said that Heidenreich, 48, would in,18 August 2011, page 1). financial results leave his current post on 31 December 2011, The committee’s recommendation will now Devising OTC strategies 20 and join its executive board on 1 January 2012. be forwarded to Germany’s ministry of health for devices – A look at the He will take charge of the company following for further consideration. pros and cons of registering its annual general meeting on 26 April 2012. An earlier proposal to reverse-switch para- OTC products as medical devices in Europe Professor Reinhard Pöllath – chairman of cetamol from non-prescription to prescription- Beiersdorf’s supervisory board – pointed out only status was removed from the agenda for REGULARS that Heidenreich had 15 years of experience in the committee’s July meeting, after Germany’s leading an international branded goods com- federal institute for drugs and medical devices, Events – Our regular listing 16 pany and had transformed Hero from a small BfArM, decided to conduct a thorough review People – Takeda places Morich 23 firm competing with larger competitors to an of all analgesic ingredients (OTC bulletin,29 in charge of Nycomed ■ Continued on page 14 July 2011, page 16). OTC14-10-11p2-3FIN.qxd 11/10/11 09:38 Page 2 OTC14-10-11p2-3FIN.qxd 11/10/11 09:38 Page 3 COMPANY NEWS OTC Mergers & Acquisitions Japan’s Santen to buy Novagali Pharma apan’s Santen Pharmaceutical is set to ac- however, is its Cationorm non-prescription treat- Jquire the French ophthalmology specialist ment for dry-eye symptoms. Novagali Pharma in a deal that values Novagali As of 31 December 2010, Cationorm had at around C100 million. been introduced by marketing partners in 10 Akira Kurokawa,Santen’s president and countries around the world, Novagali pointed chief executive officer,said that the deal would out, adding that earlier this year the company strengthen the ophthalmic-products company’s had signed an exclusive distribution agreement global business platform. This was one of San- for Canada and the US with Ardeo. ten’s long-term strategic aims, included in its In 2010, Cationorm had generated sales of business plan for 2020 as well as in its med- C0.6 million, Novagali pointed out, noting that ium-term management plan for 2011-2013. the brand’s turnover in the first half of 2011 Founded in 2000, Novagali develops and had been C0.4 million. Santen will gain Novagali’s Cationorm OTC brand for commercialises products for various eye con- Aside from Cationorm, the company’s pipe- dry-eye symptoms ditions. Its only commercially-available product, line includes products for treating severe dry- eye symptoms, chronic allergies, glaucoma, ret- pany noted, its offer per share would be in- inopathies and diabetic macular oedema. creased to C6.25. OTC bulletin Under the terms of the deal, Santen – which Based in Osaka, Japan, Santen reported sales has already secured agreements to acquire a of ¥111 billion (C1.09 billion) in the year end- 14 October 2011 Number 370 50.55% stake in Novagali – has launched a ed 31 March 2010 from its portfolio of ophthal- C6.15 per share tender offer to buy the remain- mic prescription and OTC medicines and med- Editor & Publisher: Deborah Wilkes ing 49.45% of the French firm’s stock, which ical devices. Associate Editors: Aidan Fry is in free float on the NYSE Euronext market. Santen’s range of OTC products, marketed Mike Rice If by the end of the tender process, Santen under the Sante brand name, accounted for 4.7% Business Editor: Matt Stewart had acquired 95% of Novagali’s stock, the com- or ¥5.2 billion of the company’s total sales. Assistant Editors: Jenna Lawrence OTC David Wallace Advertising Controller: Debi Minal Mergers & Acquisitions Marketing Manager: Val Davis Editorial, Subscription and Advertising EU approves P&G’s deal with Teva enquiries should be addressed to: OTC bulletin, OTC Publications Ltd, 54 Creynolds Lane, Solihull, he European Commission has approved combine the two companies’ OTC operations West Midlands B90 4ER, UK. T Procter & Gamble’s acquisition of “impor- in all markets outside of North America and Tel: +44 1564 777550. Fax: +44 1564 777524. tant parts” of generics giant Teva Pharmaceuti- will have annual sales of more than US$1 bil- E-mail: [email protected]. cal Industries’ OTC business, as the consumer lion (C 747 million) on formation. Subscriptions healthcare partnership between the two firms The Israeli firm believes this could rise to Annual subscriptions to OTC bulletin in Europe are £625.00 for single copies and £355.00 for additional copies to the same ad- starts to take shape. become US$4 billion within a few years. dress, including delivery. Subscriptions to addresses outside Eur- There had been some concern over the Teva will assume global manufacturing re- ope are subject to an additional charge of £30.00 to cover postage. Subscription enquiries in Korea should be directed to Pharma deal’s impact on competition, particularly in sponsibility for both the joint venture and Proc- Koreana Ltd, 14th Floor,KTB Network Building, 826-14 Yeoksam- the Dutch OTC laxatives market and the Aus- ter & Gamble’s North American business. dong, Kangnam-gu, Seoul 135-080, Korea (Tel: +82 2 554 9591; Fax: +82 2 563 8289; E-mail: [email protected]). trian OTC antitussives category,according to Advertising the Commission. Reshape global OTC market Advertising rates and data are available on request from the ad- However, despite the merged entity having Announcing the deal in March, Shlomo Yani, dress above or at www.otc-bulletin.com. About OTC bulletin a high market share in some market segments, Teva’s president and chief executive officer,in- OTC bulletin is published 20 times a year by OTC Publications the Commission concluded it would “face suf- sisted the partnership had the “potential to re- Limited: twice monthly in February,March, April, May,June, Sep- tember,October and November; and monthly in December,Jan- ficient competition in the markets concerned”. shape the entire global OTC market”. Teva uary,July and August. A subscription to OTC bulletin includes would deliver the world’s largest portfolio of the weekly electronic newsflash, news@OTCbulletin,which is published around 45 times a year. OTC bulletin is printed by the Wider OTC partnership medicines as well as bring extensive expertise Warwick Printing Company Limited, Caswell Road, Leamington The deal forms part of a wider agreement in developing, registering and making those Spa CV31 1QD, UK.
Recommended publications
  • Understanding the FTC's Monetary Equitable Remedies Under Section

    Understanding the FTC's Monetary Equitable Remedies Under Section

    Understanding the FTC’s monetary equitable remedies under Section 13(b) for antitrust violations By Gerald A. Stein, American Bar Association — Fall 2019 Until recently the Federal Trade Commission’s ability to seek monetary equitable remedies (particularly disgorgement and restitution) for alleged antitrust violations— whether ongoing, impending, or stale— went virtually unchallenged. After it first gained statutory authority under Section 13(b)1 of the FTC Act to bring suit in federal district court to preliminarily enjoin conduct that “is violating, or is about to violate” the antitrust laws, the FTC successfully convinced many federal courts that Section 13(b) also impliedly allowed the FTC to seek standalone permanent injunctions and monetary equitable remedies regardless of whether a defendant’s alleged anticompetitive conduct was ongoing or completed long ago.2 The FTC brought few antitrust cases in the years following the enactment for alleged antitrust violations pursuant to Section 13(b) where the alleged of Section 13(b) in 1973, and the agency formalized its conservative anticompetitive conduct was neither ongoing nor imminent. Next, in approach in its unanimously approved 2003 Policy Statement on Monetary FTC v. Credit Bureau Center LLC,5 the Seventh Circuit vacated an award for Equitable Remedies in Competition Cases. In 2012, however, the FTC restitution in a consumer protection case based on its determination that abruptly, and without providing an opportunity for public comment, Section 13(b) authorizes only restraining orders and injunctions. And, in a withdrew its 2003 Policy Statement, asserting that it created “an overly third case that is still pending, FTC v.
  • Responding to Mylan's Inadequate Tender Offer

    Responding to Mylan's Inadequate Tender Offer

    Responding To Mylan’s Inadequate Tender Offer: Perrigo’s Board Recommends That You Reject the Offer and Do Not Tender September 2015 Important Information Forward Looking Statements Certain statements in this presentation are forward-looking statements. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control, including future actions that may be taken by Mylan in furtherance of its unsolicited offer. These and other important factors, including those discussed under “Risk Factors” in the Perrigo Company’s Form 10-K for the year ended June 27, 2015, as well as the Company’s subsequent filings with the Securities and Exchange
  • 2020 Annual Report Products

    2020 Annual Report Products

    Products 2020 Annual Report From the CEO Dear Fellow Shareholders, Perrigo’s transformation to a pure-play Consumer Self-Care Company has come a long way LQMXVWWZRVKRUW\HDUV:HKDYHUHVWRUHGVXVWDLQDEOHWRSOLQHJURZWKGHOLYHUHGRQRXU¿QDQFLDO SURPLVHVUHFRQ¿JXUHGRXUSRUWIROLRRIEXVLQHVVHVXSGDWHGWKH,7LQIUDVWUXFWXUHDQGSURFHVVHV of the Company, expanded capacity, upgraded leadership talent, installed business intelligence capabilities, built a new product pipeline of over $500 million and re-instilled a sense of pride and energy among our 11,000 team members. Making this even more remarkable, is that we kept the WUDQVIRUPDWLRQRQWUDFNLQWKHIDFHRIWKHJOREDO&29,'SDQGHPLF,KRSH\RXDUHDVSURXGRI3HUULJR¶VJOREDOWHDP DV,DPIRUKRZWKH\ZRUNHGWRNHHSHDFKRWKHUVDIHNHSWRXUHVVHQWLDOSURGXFWVÀRZLQJDQGNHSWRXUWUDQVIRUPDWLRQ to a consumer self-care company on track through all of the personal and professional uncertainty that came their way LQ7KH\DUHKHURHV As a result of their efforts, Perrigo delivered strong net sales growth for the second year in a row in 2020 and World-wide Consumer sales reached a new record high. Equally important, the team stabilized adjusted operating income after a few years of decline even as we invested over $50 million in our business and overcame $35 million RIXQSODQQHGKHDGZLQGVGXHSULPDULO\WR&29,'UHODWHGVDIHW\FRVWVDQGEXVLQHVVLPSDFWIURPWKHZHDNFROG FRXJKDQGÀXVHDVRQUHODWHGWR&29,'¶VLPSDFWRQSXEOLFOLIH$OOLQDOOZHKDGDYHU\VWURQJ\HDU Our transformation efforts reached an essential milestone after the year closed when we announced the sale of RXU3UHVFULSWLRQ3KDUPDFHXWLFDOVEXVLQHVVWR$OWDULV&DSLWDO3DUWQHUV//&7KHWUDQVDFWLRQUHLQIRUFHVRXUDELOLW\
  • Pharma Pricing, Non-Profit Ties Get Increasing Scrutiny from Prosecutors

    Pharma Pricing, Non-Profit Ties Get Increasing Scrutiny from Prosecutors

    REGULATORY UPDATE REGULATORY UPDATE CONSUMER DRUGS Pediatric Rare Disease Voucher Japan Wants EMA To Stay In Digital Marketing: Health Care Brands’ Program Faces Expiration, p. 12 UK Post-Brexit, p. 15 Window Into Consumers’ Lives, p. 20 Pharma intelligence Pinkpink.pharmamedtechbi.comSheetVol. 78 / No. 38 September 19, 2016 informa Mylan NV was subpoenaed for material Pharma Pricing, Non-Profit Ties Get about the pricing of its generic doxycycline and communications with competitors. And Valeant Pharmaceuticals International Inc. is Increasing Scrutiny From Prosecutors facing several probes about its pricing and BRENDA SANDBURG [email protected] patient assistance programs (see chart, p. 5). Mylan’s doxycycline price increases were called out by Sen. Bernie Sanders, I-Vt., and Rep. Elijah Cummings, D-Md., in October 2014 when they sent letters to 14 generic drug makers about the pricing of their prod- ucts. They noted that from October 2013 to April 2014, the average price charged for a 500-count bottle of 100 mg tablets had risen from $20 to $1,829, an 8,281% increase. Mylan is now under fire for repeatedly rais- ing the price of its severe allergy treatment EpiPen (epinephrine), which has increased from about $100 for a two-pack in 2008 to more than $600. Members of Congress sent a flurry of letters to the company requesting an explanation for the price hikes. And on Sept. 6, New York Attorney Gen- Shutterstock: blvdone Shutterstock: eral Eric Schneiderman announced that his office has begun an investigation into rug makers have been unable to programs, contractual agreements with Mylan with regard to EpiPen, saying a pre- shake free of government inves- pharmacy benefit managers, support of liminary review revealed that Mylan may Dtigations of their marketing and non-profit organizations, and calculation have inserted potentially anticompetitive sales practices.
  • Cfs 2015 (1).Pdf

    Cfs 2015 (1).Pdf

    Takeda Pharmaceutical Company Limited and its Subsidiaries Consolidated Financial Statements Under IFRSs and Independent Auditor's Report For the year ended March 31, 2015 Takeda Pharmaceutical Company Limited Index Items Page Independent Auditor's Report 1 Consolidated Financial Statements 【Consolidated Statement of Operations】 2 【Consolidated Statement of Operations and Other Comprehensive Income】 2 【Consolidated Statement of Financial Position】 3 【Consolidated Statement of Changes in Equity】 4 【Consolidated Statement of Cash Flows】 6 Notes to Consolidated Financial Statements 1Reporting Entity 7 2 Basis of Preparation 7 3Significant Accounting Policies 9 4Operating Segments 16 5 Selling, General and Administrative Expenses 17 6 Other Operating Income and Expenses 18 7 Finance Income and Expenses 18 8 Income Taxes 19 9 Earnings Per Share 21 10 Other Comprehensive Income 21 11 Property, Plant and Equipment 22 12 Goodwill 23 13 Intangible Assets 24 14 Investment Property 26 15 Other Financial Assets 26 16 Inventories 26 17 Trade and Other Receivables 27 18 Cash and Cash Equivalents 27 19 Assets and Disposal Groups Held for Sale 27 20 Bonds and Loans 28 21 Other Financial Liabilities 29 22 Leases 29 23 Employee Benefits 30 24 Provisions 32 25 Other Liabilities 32 26 Trade and Other Payables 32 27 Equity and Other Equity Items 33 28 Financial Instruments 33 29 Share-based Payments 39 30 Cash Flow Information 43 31 Subsidiaries and Associates 44 32 Related Party Transactions 46 33 Business Combinations 46 34 Contingent Liabilities 46 35 Subsequent
  • Plaintiff Federal Trade Commission's Post-Trial Brief

    Plaintiff Federal Trade Commission's Post-Trial Brief

    Case 2:14-cv-05151-HB Document 403 Filed 03/23/18 Page 1 of 46 UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA FEDERAL TRADE COMMISSION, Plaintiff, Case Number: 2:14-CV-5151-HB v. ABBVIE INC., et al., Defendants. PLAINTIFF FEDERAL TRADE COMMISSION’S POST-TRIAL BRIEF Armine Black Daniel S. Bradley Rebecca L. Egeland Jordy J. Hur Garth W. Huston Hannah Lamb Heather M. Johnson Thomas D. Mays Patricia M. McDermott Markus H. Meier Kara L. Monahan Lauren Peay Peter J. Taylor Matthew B. Weprin James Weingarten Attorneys for Plaintiff FEDERAL TRADE COMMISSION 600 Pennsylvania Avenue, N.W. Washington, D.C. 20580 (202) 326-2569 [email protected] Case 2:14-cv-05151-HB Document 403 Filed 03/23/18 Page 2 of 46 TABLE OF CONTENTS TABLE OF AUTHORITIES ........................................................................................................ ii KEY PERSONNEL ...................................................................................................................... vi I. Defendants’ objectively baseless lawsuits used the governmental process as an anticompetitive weapon .................................................................................................... 2 A. Defendants enjoyed substantial benefits from the collateral injuries their baseless lawsuits inflicted on Teva and Perrigo ...................................................... 3 B. The evidence at trial supports liability even under Defendants’ erroneous view that PRE requires proof that Defendants knew their lawsuits were baseless .........
  • Medical Products Baxter’S Medical Products* Business Manufactures Products Used in the Delivery of Fluids and Drugs to Patients

    Medical Products Baxter’S Medical Products* Business Manufactures Products Used in the Delivery of Fluids and Drugs to Patients

    Baxter International Inc. Expanding Capabilities in BioSurgery In 2010, Baxter acquired ApaTech, an orthobiologics company with manufacturing and R&D facilities in the United Kingdom. Apatech’s leading product, ACTIFUSE, a synthetic bone graft material, is marketed in the United States, Europe and other countries around the world, and allows Baxter to enter the emerging bone fusion market. ApaTech’s product Applicator for ACTIFUSE pipeline complements other Baxter capabilities in biosurgery. Also in 2010, Baxter announced FDA approval of TachoSil® (Absorbable Fibrin Sealant Patch) for use as an adjunct to hemostasis in cardiovascular surgery. TachoSil® is the first and only adjunctive hemostatic agent available in the United States that combines a collagen patch with a coating of human coagulation factors. TachoSil® is a patented product of Nycomed, a global pharmaceutical company headquartered in Zurich, Switzerland, and is available in a number of markets outside the United States. Baxter holds exclusive U.S. marketing and distribution rights. Seasonal Influenza Vaccine Latest to Leverage Vero Cell Platform In 2010, Baxter received approval of PREFLUCEL, a vaccine for seasonal influenza, in Austria and the Czech Republic. PREFLUCEL is made using Baxter’s Vero cell culture platform and does not contain an adjuvant or preservatives. Baxter expects to launch PREFLUCEL in other European countries in 2011, PREFLUCEL vaccine and is working with the FDA on licensure in the United States. In addition, Baxter continues to expand its development and licensing activities for PREFLUCEL through direct regional and national licensing processes. In 2010, Baxter announced an agreement with Takeda Pharmaceutical Company Limited in Japan for the development, production and supply of cell culture-based influenza vaccines for the Japanese market.
  • DURECT CORPORATION (Exact Name of Registrant As Specified in Its Charter)

    DURECT CORPORATION (Exact Name of Registrant As Specified in Its Charter)

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-31615 DURECT CORPORATION (Exact name of registrant as specified in its charter) Delaware 94-3297098 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 10260 Bubb Road Cupertino, CA 95014 (Address of principal executive offices, including zip code) Registrant’s telephone number, including area code: (408) 777-1417 Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Name of Each Exchange on Which Registered Common Stock $0.0001 par value per share The NASDAQ Stock Market LLC Preferred Share Purchase Rights (NASDAQ Global Market) Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES NO Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15 of the Act. YES NO Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period than the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
  • Perrigo Board of Directors

    Perrigo Board of Directors

    Perrigo Company plc Board of Directors and Their Compensation (as of August 7, 2019) Bradley A. Alford, 62, has been a director of Perrigo since February 2017. Mr. Alford joined Advent International Corporation, a global private equity firm, in 2014 as an Industry Advisor and moved to Operating Partner in March of 2016. From 2006 to 2013, Mr. Alford was Chairman and Chief Executive Officer of Nestlé USA. Mr. Alford also served as CEO and President of Nestlé Brands Company. He currently serves as a director of Avery Dennison Corporation since April 2010 and previously served as a director of Conagra Brands, Inc. from July 2015 to September 2018. Throughout his career, Mr. Alford has been focused on developing brands, initiatives to improve processes and facilitate best practices across an organization. Rolf A. Classon, 73, has been a director of Perrigo since May 2017. Mr. Classon served as Interim President and Chief Executive Officer of Hillenbrand Industries, a global diversified industrial company, from May 2005 until March 2006. From 2002 until June 2004, Mr. Classon served as Chairman of the Executive Committee of Bayer Healthcare AG, a subsidiary of Bayer AG. Mr. Classon served as President of Bayer Diagnostics from 1995 to 2002 and as Executive Vice President from 1991 to 1995. Prior to 1991, Mr. Classon held various management positions with Pharmacia Corporation. Mr. Classon serves as a director of Fresenius Medical Care AG and Co. since May 2012, and Catalent, Inc. since July 2014. Mr. Classon also served as a director of Hill-Rom Holdings, Inc., from July 2001 to March 2018, Aerocrine AB, Stockholm from May 2013 to July 2015 and Auxilium Pharmaceuticals from July 2005 to January 2015 and served as a director of Tecan Group, Ltd.
  • View Annual Report

    View Annual Report

    A Proven Formula for Delivering Superior Shareholder Value A A Proven Formula for Delivering Superior Shareholder Value Corporate Profile From its beginnings in 1887 as a packager of generic home remedies, Perrigo Company plc, headquartered in Ireland, has grown to become the world’s largest manufacturer of over-the-counter (OTC) products and supplier of infant formulas for the store brand market, and is now a top five global OTC consumer goods and pharmaceutical company. In addition to receiving royalties from Multiple Sclerosis drug Tysabri®, the Company is also a leading provider of branded OTC products and generic extended topical prescription products. Perrigo provides Quality Affordable Healthcare Products® across a wide variety of product categories and geographies, primarily in North America, Europe, and Australia, as well as in other markets, including Israel and China. Perrigo 1 Fellow Shareholders, On behalf of the Perrigo management team and the over 13,000 Perrigo employees worldwide, I am extremely proud to report our tenth consecutive year of record earnings. By effectively executing our ‘Base Plus Plus Plus’ strategy, we continued our consistent track record of delivering superior shareholder returns, with a total shareholder return of over 970% since 2007. Joseph C. Papa Chairman, President, and Chief Executive Officer Over the past eight years, we have transformed Perrigo I also want to address the recent attempts by Mylan N.V. into a top five global OTC pharmaceutical company. (Mylan) to acquire Perrigo. As we have consistently In fiscal 2015, we took significant steps to build on this maintained since April, we believe Mylan’s offer platform through three highly strategic acquisitions that substantially undervalues Perrigo and is not in the best further strengthened our global scale and distribution interests of our shareholders.
  • Perrigo Annual Report 2020

    Perrigo Annual Report 2020

    Perrigo Annual Report 2020 Form 10-K (NYSE:PRGO) Published: February 27th, 2020 PDF generated by stocklight.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 001-36353 Perrigo Company plc (Exact name of registrant as specified in its charter) Ireland N/A (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) The Sharp Building, Hogan Place, Dublin 2, Ireland D02 TY74 +353 1 7094000 (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Ordinary shares, €0.001 par value PRGO New York Stock Exchange Securities registered pursuant to Section 12(g) of the Act: None (Title of Class) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 of Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
  • 0811 Bok.Indb

    0811 Bok.Indb

    «Hun så veldig fl ink ut... Ansette henne?» 'SFNHBOHTSJL)3 XXXBTTFTTJPOP IT FINANS MARKED ENGINEERING Ring UpSource på 55 70 70 25 for en profesjonell vurdering. A-AVIS FOTO: ANITA MYKLEMYR ANITA FOTO: 14. MARS 2008 NR. 11 – 21. ÅRGANG – LØSSALG KR 25 Advokat Erling Grimstad: Kjerstin Fyllingen, –NAIV STATLIG TrygVesta: HOLDNING TIL HOPPET I LEDERROLLEN ETIKK SIDE 38 SIDE 32 FOTO: INGAR HAUG STEINHOLT/SCANPIXSTEINHOLT/SCANPIX Lær deg å like TIDS- Banker OPTIMISTEN SIDE 24–26 børsgutta FOTO: STIAN LYSBERG SOLUM/SCANPIX i ledelse Christian Rynning- Ukeavisen Ledelse har vurdert nærmere Tønnesen, Norske Skog: 40 toppsjefer. Etter å ha snakket med Papirtigeren 15 personer om Åse Aulie Michelets SIDE 4 sterke og svake sider som leder, kan vi GOD PÅSKE! konstatere at hun er noe av det beste Neste utgavegave av som kan oppdrives av sjefer her til lands. Ukeavisenn På bunnen av toppsjef-lista ligger sjefen Ledelse hennes, John Fredriksen. SIDE 15–20 kommer 28. mars. LEDERVERKTØY: SLIK BEHANDLER DU JOBBSØKERE SIDE 28 Åpen kontorløsning kan redusere kostnader og øke kompetansen i virksomheten! Mouversi har lang erfaring med gjennomføring av prosjekter ved etablering av åpen kontorløsning. Riktig fysisk utforming av arealet - Etablering av team - Økt medarbeiderkompetanse — Fornøyde kunder Utprøvd metode og gode resultater kan dokumenteres. Kontakt oss for rådgiving og prosessgjennomføring. Mouversi betyr å flytte på seg, både fysisk og samtidig flytte grenser for egne prestasjoner. mouversi flytter mennesker og virksomheter Fjordgt 9, 7011 Trondheim, Mobil: 93201177, Mail: [email protected] www.aapenkontorlosning.no 2 NR. 11 – FREDAG 14. MARS 2008 – UKEAVISEN LEDELSE LEDERPLASS FOTO: SVEIN ERIK FURULUND/SCANPIX Tilliten i markedet til Rynning-Tønnesen har fått et knekk, men det er for tidlig å regne med at han ikke får fortsette som konsernsjef i Norske Skog.